O,O-diacetyl tartaric acid anhydride: RN given refers to (3R-trans)-isomer; used to monitor propranolol in human plasma; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 513914 |
SCHEMBL ID | 1333553 |
MeSH ID | M0166056 |
Synonym |
---|
6283-74-5 |
nsc-7712 |
diacetyl-4-tartaric anhydride treated bsa |
acetic acid 4-acetoxy-2,5-dioxo-tetrahydro-furan-3-yl ester |
(+)-o,o'-diacetyl-l-tartaric anhydride, 97% |
AKOS000277852 |
[(3r,4r)-4-acetyloxy-2,5-dioxooxolan-3-yl] acetate |
D1911 |
(+)-diacetyl-l-tartaric anhydride |
d7xnf76o0k , |
o,o-diacetyl tartaric acid anhydride |
unii-d7xnf76o0k |
einecs 228-502-7 |
(3r-trans)-dihydro-2,5-dioxofuran-3,4-diyl diacetate |
nsc 7712 |
SCHEMBL1333553 |
(r,r)-2,3-diacetoxy-1,4-butanedioic anhydride |
(2r,3r)-di-o-acetyltartaric acid anhydride |
di-o-acetyl-l-tartaric anhydride |
(3r,4r)-2,5-dioxotetrahydrofuran-3,4-diyl diacetate |
l-diacetyltartaric anhydride |
diacetyltartaric anhydride |
diacetyltartaric acid anhydride |
2,5-furandione, 3,4-bis(acetyloxy)dihydro-, (3r,4r)- |
o,o'-diacetyl-l-tartaric anhydride |
diacetyltartaric anhydride, l- |
mfcd00037918 |
(3r,4r)-4-(acetyloxy)-2,5-dioxooxolan-3-yl acetate |
(+)-o,o'-diacetyl-l-tartaric anhydride, purum, >=97.0% (nt) |
AS-68738 |
F0001-1696 |
(3r,4r)-2,5-dioxotetrahydrofuran-3,4-diyldiacetate |
D78416 |
Q27276225 |
A868343 |
184636-89-3 |
rel-(3r,4r)-2,5-dioxotetrahydrofuran-3,4-diyl diacetate |
(+)-o,o'-diacetyl-l-tartaric anhydride |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (20.00) | 18.7374 |
1990's | 3 (60.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.80) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |